Anna-Mária Tökés1, A Marcell Szász2, Franciska Geszti3, Lilla V Lukács4, István Kenessey2, Eszter Turányi5, Nóra Meggyesházi5, István A Molnár6, János Fillinger7, Ibolya Soltész7, Katalin Bálint8, Zoltán Hanzély9, Gabriella Arató10, Miklós Szendröi10, Janina Kulka2. 1. MTA-SE Tumor Progression Research Group, 2nd Department of Pathology, Semmelweis University, Budapest, Hungary 2nd Department of Pathology, Semmelweis University, Budapest, Hungary. 2. 2nd Department of Pathology, Semmelweis University, Budapest, Hungary. 3. 2nd Department of Pathology, Semmelweis University, Budapest, Hungary Department of Oncodermatology, National Institute of Oncology, Budapest, Hungary. 4. Department of Radiology, Ministry of Defense State Health Centre, Budapest, Hungary. 5. 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. 6. 1st Department of Surgery, Semmelweis University, Budapest, Hungary. 7. Department of Pathology, Korányi National Institute for Tuberculosis and Pulmonology, Budapest, Hungary. 8. 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary Department of Pathology, National Institute of Neurosurgery, Budapest, Hungary. 9. Department of Pathology, National Institute of Neurosurgery, Budapest, Hungary Department of Neuropathology, Southern General Hospital, Glasgow, UK. 10. Department of Orthopaedics, Semmelweis University, Budapest, Hungary.
Abstract
AIMS: To assess the expression of the following cell cycle regulatory proteins in primary metastatic breast carcinomas (MBCs) and on availability in matched distant metastases (DMs): Ki67, cyclin A, geminin and aurora-kinase A (aurkA); and to compare the expression of these markers in early MBC (EMBC) and late MBC separated into groups according to median time point on metastatic event occurred (28 months). METHODS: The expression of the above mentioned markers was analysed in a total of 47 primary MBCs and 59 DMs (out of which 37 were pairs) by immunohistochemistry. Fourteen breast carcinomas with no relapse over a 10-year follow-up period were utilised as control cases (CBC). RESULTS: Among the MBCs, 22 metastasised to the bone, 4 to the lung and 21 to the central nervous system (CNS). Geminin (p<0.001) and Ki67 (p=0.001) were increased in the MBCs while aurkA and cyclin A showed no difference when compared with CBCs. There were no differences between aurkA, cyclin A and geminin expression in MBCs and DMs in general. Expression of Ki67 was, however, elevated (p=0.027) in DMs. In CNS metastases all markers showed elevated expression as compared to MBCs. In bone metastases, geminin was lower (p<0.001) compared with primary MBCs. In the metastases of the lung, the evaluated markers did not show different expression. According to the median follow-up until the metastatic event, Ki67 was found to be significantly elevated in EMBC (p=0.018). CONCLUSIONS: Ki67 index and geminin distinguish a fraction of MBC with worse prognosis, showing increased levels in the latter in comparison to CBC being tumour-free over a 10-year follow-up period. Ki67 could possibly identify a group of MBCs that develop early DMs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIMS: To assess the expression of the following cell cycle regulatory proteins in primary metastatic breast carcinomas (MBCs) and on availability in matched distant metastases (DMs): Ki67, cyclin A, geminin and aurora-kinase A (aurkA); and to compare the expression of these markers in early MBC (EMBC) and late MBC separated into groups according to median time point on metastatic event occurred (28 months). METHODS: The expression of the above mentioned markers was analysed in a total of 47 primary MBCs and 59 DMs (out of which 37 were pairs) by immunohistochemistry. Fourteen breast carcinomas with no relapse over a 10-year follow-up period were utilised as control cases (CBC). RESULTS: Among the MBCs, 22 metastasised to the bone, 4 to the lung and 21 to the central nervous system (CNS). Geminin (p<0.001) and Ki67 (p=0.001) were increased in the MBCs while aurkA and cyclin A showed no difference when compared with CBCs. There were no differences between aurkA, cyclin A and geminin expression in MBCs and DMs in general. Expression of Ki67 was, however, elevated (p=0.027) in DMs. In CNS metastases all markers showed elevated expression as compared to MBCs. In bone metastases, geminin was lower (p<0.001) compared with primary MBCs. In the metastases of the lung, the evaluated markers did not show different expression. According to the median follow-up until the metastatic event, Ki67 was found to be significantly elevated in EMBC (p=0.018). CONCLUSIONS: Ki67 index and geminin distinguish a fraction of MBC with worse prognosis, showing increased levels in the latter in comparison to CBC being tumour-free over a 10-year follow-up period. Ki67 could possibly identify a group of MBCs that develop early DMs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
BREAST CANCER; IMMUNOHISTOCHEMISTRY; PROLIFERATION
Authors: Aaron Mobley; Shizhen Zhang; Jolanta Bondaruk; Yan Wang; Tadeusz Majewski; Nancy P Caraway; Li Huang; Einav Shoshan; Guermarie Velazquez-Torres; Giovanni Nitti; Sangkyou Lee; June Goo Lee; Enrique Fuentes-Mattei; Daniel Willis; Li Zhang; Charles C Guo; Hui Yao; Keith Baggerly; Yair Lotan; Seth P Lerner; Colin Dinney; David McConkey; Menashe Bar-Eli; Bogdan Czerniak Journal: Sci Rep Date: 2017-01-19 Impact factor: 4.379